Reyataz, Atazanavir Sulfate News

SUMMARY: On the eve of World AIDS Day, the National AIDS Fund and Bristol-Myers Squibb -- which produces antiretroviral drugs including efavirenz and atazanavir -- announced a plan to launch in January 2010 a new long-term initiative, dubbed "Positive Charge," to help overcome barriers to HIV treatment and provide support to patients.

According to the most recent report from the Centers for Disease Control and Prevention, more than one million people are living with HIV and the annual incidence of new infections was 56,300 in the U.S.1 It is critical that effective and tolerable medicines are available to patients initiating antiretroviral therapy.

Main Category: HIV / AIDS Also Included In: Cardiovascular / Cardiology Article Date: 21 Jul 2009 Patients taking Boehringer Ingelheim's HIV drug Viramune have a lower risk of developing cardiovascular disease than those taking Bristol-Myers Squibb's treatment, Reyataz, according to a study released on Monday at the 5th International AIDS Society ...